<DOC>
	<DOCNO>NCT01266187</DOCNO>
	<brief_summary>Is perioperative chemotherapy base FOLFOX Cetuximab ( K-RAS wild-type ) associate high rate postoperative complication patient resectable colorectal liver metastasis compare adjuvant FOLFOX chemotherapy ? Are differences disease free survival periand postoperative treatment patient &gt; 3 liver metastasis least one metastasis &gt; = 5 cm diameter ?</brief_summary>
	<brief_title>Treatment Regimens Patients With Resectable Liver Metastases ( PANTER Study )</brief_title>
	<detailed_description>In recent year chemotherapy base FOLFOX cetuximab become standard treatment patient colorectal liver metastasis . Recently , analysis CELIM trial report response rate 70 % patient initially unresectable colorectal liver metastasis treat FOLFOX + Cetuximab . 46 % patient metastases R0 R1 resect ablation radiofrequency overall 34 % R0 resection rate . In recent study , adjuvant chemotherapy FOLFOX lead prolongation disease free survival successful resection colorectal liver metastasis , sufficient data concern perioperative regimen . In one study Nordlinger et al . trend progression-free survival could reach patient receive perioperative FOLFOX-therapy , without reach statistical significance . Furthermore patient display significantly high rate postoperative complication morbidity . Although advantage perioperative treatment proven , concept become popular recent year , mainly lack guideline . Thus aim study compare complication rate therapeutical concept . Furthermore , secondary objective ( disease-free survival , overall survival , resection rate , response rate , toxicity quality life ) use estimate efficacy , feasibility , safety regimen . Perioperative treatment probably well efficacy patient high tumor burden ( &gt; 3 liver metastases one metastasis &gt; = 5 cm diameter ) effect disease free survival investigate subgroup analysis .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Signed write informed consent obtain prior studyspecific procedure . Age &gt; 18 year Proven KRAS wildtype primary tumour metastasis tissue Diagnosis resectable metachronous metastasis complete resection ( R0 ) primary tumour without gross microscopic evidence residual disease . Diagnosis resectable synchronous metastasis complete resection ( R0 ) primary tumour 1 month study Diagnosis resectable synchronous metastasis sufficient evidence ( i.e. , CT scan diagnostic laparoscopy ) primary tumour liver metastases completely resected procedure resection primary delay 34 month . Negative pregnancy test Highly effective contraception treatment least 3 month thereafter woman ( define pearl index &lt; 1 ) men , risk conception exists Planned start study medication 0 3 week post randomization ECOG performance status 0 1 ( Appendix 1 ) Adequate hematology : neutrophil &gt; 1,5 /nl , platelet &gt; 100/nl , INR &lt; 1,5 , aPTT &lt; 1,5 x UNL Adequate biochemistry : total bilirubin &lt; 1,5 x UNL , ASAT ALAT &lt; 5 x UNL , alkaline phosphatase &lt; 5 x UNL , serum creatinine &lt; 1,5 , x UNL . Patients relationship dependence sponsor investigator Patients committed institution ( courtordered official order ) Extrahepatic metastatic disease Proven KRAS mutation unknown KRAS mutational status tumour tissue Oxaliplatinbased adjuvant chemotherapy within 1 year randomization Neuropathy &gt; = grade 3 ( NCICTC V4.0 ) prior oxaliplatinbased chemotherapy Any prior chemotherapy metastatic disease Previous treatment EGFR antibodies Prior noncolorectal malignancy , except adequately treat basalioma skin carcinoma situ cervix . Bleeding diathesis coagulation disorder Females positive pregnancy test ( within 14 day treatment start ) breast feed Fertile woman ( &lt; 2 year last menstruation ) woman childbearing potential willing use effective mean contraception History psychiatric disability judge investigator clinically significant , preclude informed consent interfere compliance drug intake Clinically significant ( i.e . active ) cardiovascular disease , e.g . cerebrovascular accident ( &lt; 6 month prior randomization ) , myocardial infarction ( &lt; 1 year prior randomization ) , Congestive heart failure ( NYHA Grades III IV ) , uncontrolled hypertension receive chronic medication , unstable angina pectoris , significant arrhythmia Known peripheral neuropathy , include oxaliplatininduced &gt; = grade 1 ( NCICTC V4.0 ) . Absence deep tendon reflex sole neurologicl abnormality render patient ineligible Known DPDdeficiency ( Dihydropyrimidinedehydrogenase ) Organ allografts require immunosuppressive therapy Serious , nonhealing wound , ulcer bone fracture Serious intercurrent infection ( uncontrolled require treatment ) Current recent ( within 28 day prior randomisation ) treatment another investigational drug participation another investigational study Any contraindication study medication ( include auxiliary substance ) Patients unwilling consent save propagation pseudonymized medical data study reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>FOLFOX</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>cetuximab</keyword>
</DOC>